stockrow
Friday 6 November 2026
Export DNLI’s income statement to Excel — free account
Denali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
20.12
0.40
+2.03%
Follow DNLI
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
171.93 | 16.11 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(33.16) | (49.67) | — | — | |
P/B ratio |
4.20 | 5.77 | — | — | |
Price to Tangible BV |
4.37 | 6.02 | — | — | |
EV/Sales |
149.38 | 13.76 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(7.62) | (9.48) | — | — | |
EV/FCF |
(7.52) | (9.40) | — | — | |
Quick Ratio |
5.62 | 7.93 | 8.97 | 8.82 | |
Current Ratio |
6.21 | 8.37 | 9.28 | 9.16 | |
Net Debt/EBITDA |
4.11 | 5.49 | 7.23 | 6.33 | |
Debt/Assets |
0.43% | 0.47% | 0.44% | 0.48% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.02 | 0.26 | 0.00 | 0.00 | |
Operating CF/Net income |
(1.67) | 0.76 | 1.02 | 0.77 | |
Capex/Depreciation |
(0.39) | (0.38) | (1.55) | (1.25) | |
Research and Development Expense of Revenue |
596.82% | 2,691.98% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
210.85% | 1,006.74% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.00 | |
Share Based Compensation of Revenue |
128.58% | 635.82% | 0.00% | 0.00% | |
Graham Net Nets |
0.07 | 0.09 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(8.36%) | (11.04%) | — | — | |
Free Cash Flow Yield |
(11.56%) | (9.08%) | — | — | |
Revenue per Share |
0.09 | 0.02 | 0.00 | 0.00 | |
Operating CF per Share |
(0.62) | (0.52) | (0.70) | (0.57) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.63) | (0.52) | (0.72) | (0.58) | |
Cash per Share |
2.74 | 3.79 | 5.29 | 5.03 | |
Shareholders Equity per Share |
4.92 | 4.46 | 4.96 | 5.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.92 | 4.46 | 4.96 | 5.87 | |
Free Cash Flow |
(118.45) | (97.81) | (133.67) | (100.06) | |
Working Capital |
496.45 | 663.84 | 912.60 | 802.31 | |
Capital Expenditures |
(1.01) | (0.80) | (2.47) | (1.52) | |
Net Current Asset Value |
262.06 | 431.15 | 682.83 | 769.57 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.06 | 0.22 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
11.94 | 1.96 | — | — | |
Average Payables |
10.22 | 11.33 | 24.42 | 5.82 | |
Average Assets |
1,155.83 | 1,162.10 | 1,268.68 | 1,259.52 | |
Average Common Equity |
926.29 | 931.12 | 1,024.39 | 1,121.72 |
Columns are period end dates · fundamentals updated 5 Nov 2026